Loading...
Market
What will be the first major side effect report for TECELRA by the end of 2024?
2
Resolution / Starting Odds
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
FDA adverse event reporting system or major medical journals
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA, First Engineered Cell Therapy for Solid Tumor
Aug 2, 2024, 09:45 AM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking the first approved engineered cell therapy for a solid tumor. This gene therapy is indicated for the treatment of adults with unresectable or metastatic synovial sarcoma, a rare form of cancer that develops in the soft tissues of the body. The approval represents a significant milestone for the oncology community, extending the power of immunotherapies into difficult-to-reach sarcomas. Patients eligible for this treatment must have tumors expressing MAGE-A4 and be positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P.
View original story
Similar markets
Advanced Synovial Sarcoma • 25%
Other Sarcomas • 25%
Other Solid Tumors • 25%
Combination Therapies • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No significant side effects • 25%
Nausea • 25%
Fatigue • 25%
Diarrhea • 25%
Other • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No major side effects • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 50 • 25%
50 to 100 • 25%
100 to 200 • 25%
More than 200 • 25%